#2. Biogen (BIIB)
Cashtaggers buzzed Monday about this biotech winning FDA approval for a hemophilia B treatment. The company announced Friday that the FDA gave the go-ahead for its DNA-derived treatment to control bleeding episodes in patients who have trouble clotting.
The company, which has a $72.18 billion market cap, has many approved drugs, including treatments for multiple sclerosis, leukemia and non-Hodgkin's lymphoma. Last year, the company earned $2.1 billion, excluding some items, on $6.9 billion in sales.Analysts have 20 Buy ratings and 8 holds on the stock, according to the Analyst Ratings Network. Consensus calls for a $317 price target. It currently trades at $305.12. Sentiment on the stock is 75% bullish, according to StockTwits' analytics.
One of the few good stocks to trade for today: $BIIB -- Selwyn Duijvestijn (@Marktgevoel) Mar. 31 at 09:51 AM#3. Gilead Sciences (GILD) This biotech giant with a $108 billion market cap is down nearly 16% in the past month. And that, say cashtaggers, is a buying opportunity. The stock rose 2% this morning.
$GILD $CELG $BIIB $REGN $IBB all showing strength in the pre-market, on high vol too -- Brandon (@brduke) Mar. 31 at 09:13 AMGilead is most often in the news regarding its Hepatitis C drug Sovaldi, which was approved in December last year. The drug costs $1,000 a day, which has raised the ire of some in Congress, but it can cure patients of the disease. Untreated, Hepatitis C can result in liver failure. Sovaldi isn't Gilead's only blockbuster drug. It also makes treatments for HIV/AIDS, cystic fibrosis, the flu, macular degeneration, hypertension and cardiovascular disease. That's one reason why the company brought in $3.45 billion, excluding some items, on $11.2 billion in revenues last year. Analysts have 24 buy ratings on the stock and 2 holds, according to the Analyst Ratings Network. Consensus price target is $88.92. The stock currently trades at $70.19. Sentiment on the name is 83% bullish, according to StockTwits' analytics.
$GILD @searchlight Calls working this morning. Good job. Conviction pays. -- Swingman24 (@Swingman24) Mar. 31 at 10:11 AMAt the time of publication, the author held no positions in any of the stocks mentioned. This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.